Pfizer and BioNTech Report Results of BNT162b2 to Prevent COVID-19

 Pfizer and BioNTech Report Results of BNT162b2 to Prevent COVID-19

Shots:

  • The P-III study evaluating BNT162b2 (COVID-19 Vaccine) vs PBO in >44,000 participants age ≥16 yrs with 927 confirmed symptomatic cases of COVID-19
  • The results demonstrated that BNT162b2 is 91.3% effective against COVID-19, follow-up time of at least 6 mos after the 2nd dose, 100% effective in preventing severe disease by CDC, 95.3% effective against severe COVID-19 by US FDA, effective against B.1.351 variant, safe and tolerable
  • The companies plan to share the results with worldwide regulatory agencies

Click here to­ read full press release/ article | Ref: Pfizer | Image: Bloomberg Quint

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post